History of Glenmark Life Sciences Limited

_x000D_ Incorporated in 2011, Glenmark Life Sciences Limited is involved in the manufacturing of pharmaceuticals, chemicals and chemical products, medicinal chemicals and botanical products._x000D_ _x000D_ Glenmark Life Sciences Limited’s journey began in 2001 when Glenmark Pharmaceuticals set up its Active Pharmaceutical Ingredient (API) business. In 2002, they set up a manufacturing unit at Kurkumbh, Maharashtra. In the next year, the company’s first product was registered with the US FDA (Food and Drug Administration). In the same year, they acquired a manufacturing unit of Glaxo SmithKline’s (GSK) API in Ankleshwar, Gujarat. In 2004, they started manufacturing at Mohol, Maharashtra._x000D_ _x000D_ The company’s Ankleshwar manufacturing unit was inspected by the US FDA in 2008, then by PMDA (Pharmaceuticals and Medical Devices Agency) and AFSSAPS (Agence française de sécurité sanitaire des. produits de santé), France in 2012 and by COFEPRIS (Mexico Ministry of Health) in 2013. In the same year, i.e., 2013, the company’s manufacturing unit at Dahej, Gujarat, started its operations, and it was inspected by the US FDA in 2015._x000D_ _x000D_ In 2019, the company’s API business was separated into Glenmark Life Sciences. In 2021, the company reached a milestone of 403 cumulative Drug Master Files (DMFs) across multiple markets worldwide. In the same year, Glenmark Life Sciences went public and got listed on the stock exchanges in India._x000D_ _x000D_ As of March 2023, Glenmark Life Sciences has an API portfolio of 139 molecules and caters to customers across more than 75 countries in the world, including Japan, North America, Europe, Latin America and more. They have 4 plants, where 2 are in Maharashtra, 2 are in Gujarat and 1 R&D site at Navi Mumbai. Their API plants are regularly inspected by prominent global authorities such as PMDA, the US FDA and other regulatory agencies in Europe, Canada, Russia and Korea._x000D_

Business Segments of Glenmark Life Sciences Limited 

_x000D_ The business solutions and services offered by the company are as follows:_x000D_

_x000D_
• API: This is the primary business segment of the company. Under this, the company manufactures and supplies APIs to pharmaceutical companies globally. The company’s product portfolio contains 137 APIs across various therapeutic segments, such as Cardiovascular, Central Nervous System disorders, Diabetes, Gastrointestinal health, Oncology, Pain management, and Anti-Infectives.
_x000D_

_x000D_

_x000D_
• End-to-end support: In this segment, the company offers support to their partners right from product development to analytical development and support and API and Intermediate manufacturing.
_x000D_

_x000D_ As of March 31, 2023, there are no subsidiaries of Glenmark Life Sciences Limited._x000D_

Key Personalities of Glenmark Life Sciences Limited

_x000D_ Dr Yasir Rawjee, Managing Director and Chief Executive Officer_x000D_ _x000D_ Dr Yasir Rawjee is the Managing Director and Chief Executive Officer of Glenmark Life Sciences Limited. He steers the overall operations and business strategy of the company. He holds more than 20 years of experience in the pharmaceutical industry. Before joining Glenmark Life Sciences Limited, he worked at GlaxoSmithKline in the USA, at Mylan Laboratories Limited as the head of global API operations, and also as the Senior Vice President at Matrix Laboratories Limited.